ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 164 filers reported holding ASCENDIS PHARMA A/S in Q3 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26,687 | +53.3% | 285,000 | +46.2% | 17.16% | +36.8% |
| Q2 2023 | $17,404 | +64.7% | 195,000 | +97.8% | 12.55% | +69.6% |
| Q1 2023 | $10,569 | -42.8% | 98,571 | -34.9% | 7.40% | -17.4% |
| Q4 2022 | $18,492 | -99.9% | 151,409 | +4.3% | 8.95% | -22.1% |
| Q3 2022 | $16,699,000 | +49.7% | 145,209 | +21.0% | 11.49% | +32.8% |
| Q2 2022 | $11,155,000 | -40.8% | 120,000 | -25.2% | 8.65% | -25.0% |
| Q1 2022 | $18,836,000 | +20.8% | 160,500 | +38.5% | 11.54% | +222.7% |
| Q4 2021 | $15,590,000 | +46.6% | 115,885 | +73.7% | 3.58% | -59.6% |
| Q3 2021 | $10,634,000 | +62.6% | 66,714 | +34.2% | 8.85% | +93.7% |
| Q2 2021 | $6,541,000 | +87.5% | 49,721 | +83.7% | 4.57% | +415.7% |
| Q1 2021 | $3,488,000 | -9.8% | 27,064 | +16.7% | 0.89% | -67.5% |
| Q4 2020 | $3,866,000 | – | 23,183 | – | 2.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 11,225,357 | $1,001,863,112 | 18.92% |
| Q Global Advisors, LLC | 195,000 | $17,404 | 12.55% |
| Sofinnova Investments, Inc. | 754,032 | $67,297,356 | 4.41% |
| Avoro Capital Advisors LLC | 3,580,555 | $319,564,534 | 4.34% |
| Finepoint Capital LP | 139,772 | $12,474,651 | 4.32% |
| Spyglass Capital Management LLC | 657,853 | $58,713,380 | 4.24% |
| Saturn V Capital Management LP | 78,442 | $7,000,948 | 3.88% |
| DAFNA Capital Management LLC | 135,212 | $12,067,671 | 3.30% |
| ARS Investment Partners, LLC | 289,860 | $25,870,005 | 3.02% |
| Ghost Tree Capital, LLC | 100,000 | $8,925,000 | 2.95% |